A Multi-centre, Randomised, Double-blind, Placebo-controlled, Crossover Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2016
At a glance
- Drugs GSK 2269557 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 11 Nov 2016 Status changed from recruiting to completed.
- 21 Jul 2016 Planned End Date changed from 1 Jul 2016 to 1 Oct 2016.
- 01 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov